BEIJING, China, August 24, 2026 — Jacobio Pharma (1167.HK) announced its 2026 interim results. For the first half of 2026, the Company recorded RMB731 million in revenue and RMB601 million in net profit, achieving a turnaround to profitability. The Company had approximately RMB1.68 billion in cash and RMB480 million in available bank credit facilities, representing total funding resources of approximately RMB2.16 billion, which are expected to support research and development activities for approximately the next five years.

During the reporting period, Jacobio continued to build a multi-generation portfolio targeting the RAS pathway, advancing its commercial-stage KRAS product, core clinical and next-generation therapeutic platforms.

The commercialized KRAS G12C inhibitor glecirasib (艾瑞凯®) has been included in China's National Reimbursement Drug List for second-line non-small cell lung cancer. Jacobio recognized RMB14.5 million in revenue from its partner Allist during the first half of 2026. A Phase III registrational study of glecirasib in combination with the SHP2 inhibitor JAB-3312 in first-line NSCLC, as well as a tumor-agnostic Phase II single-arm registrational study of glecirasib monotherapy, are ongoing.

Jacobio's core clinical asset, the Pan-KRAS inhibitor JAB-23E73, continued to advance globally. Dose expansion is underway in China, and a Phase Ib/III study of JAB-23E73 in combination with chemotherapy in first-line KRAS-mutant pancreatic cancer has been initiated. In the United States, dose escalation and expansion are progressing in parallel, while the collaboration with AstraZeneca is expected to broaden the development of JAB-23E73 across combination regimens and tumor types.

According to the latest clinical data, among 47 patients with second-line or later pancreatic cancer treated at potentially efficacious doses, JAB-23E73 monotherapy achieved an objective response rate (ORR) of 38.5% (10/26) and a disease control rate (DCR) of 88.5% (23/26) in second-line patients. Among all second-line or later patients, the ORR was 31.9% (15/47) and the DCR was 83.0% (38/47). JAB-23E73 also demonstrated a favorable safety profile, with Grade 3 treatment-related adverse events (TRAEs) reported in 14.0% of patients, and no dose-limiting toxicities or Grade 4–5 TRAEs observed.

For the next generation of KRAS-targeted therapies, Jacobio is advancing an EGFR-KRAS G12Di tADC, designed to enhance tumor-specific delivery and increase the exposure of KRAS inhibitors in tumor tissues, with the potential to address resistance mechanisms in indications such as colorectal cancer. The Company plans to submit an IND application for the program in the fourth quarter of 2026.

Jacobio is also developing a Pan-RASi tADC. Through tumor enrichment, the program has the potential to reduce toxicity, enable long-term treatment and offer greater potential for use in the first-line setting. A development candidate has been selected, with an IND submission planned for the second half of 2027.

In tumor immunology, Jacobio continues to advance programs including JAB-BX467, a HER2-STING iADC, and other immune-recruiting ADCs utilizing STING agonists as payloads. The iADC platform is designed to convert “cold” tumors into “hot” tumors, potentially addressing the unmet clinical needs of patients who do not respond to PD-1 therapies. The Company plans to submit an IND application for JAB-BX467 in the fourth quarter of 2026.

Jacobio also has multiple clinical-stage programs that rank among the top three globally in development progress, including the BET inhibitor JAB-8263, p53 Y220C activator JAB-30355, and Aurora A inhibitor JAB-2485. The Company is also exploring the potential of BET inhibition in autoimmune diseases.

Dr. Yinxiang Wang, Founder, Chairman and Co-CEO of Jacobio Pharma, commented:
“The first half of 2026 marked an important stage in the realization of Jacobio's value. Revenue and cash flow generated from our strategic collaborations enabled the Company to achieve a turnaround to profitability and further strengthened our ability to invest in innovation. KRAS remains one of Jacobio's most strategically important areas. Jacobio has established a multi-generation KRAS franchise, with one generation commercialized, one generation in clinical development, and the next generation in reserve. Going forward, we will remain focused on differentiated medicines with global competitive potential, accelerate the development of our core pipeline and continue translating scientific innovation into value for patients and long-term value for the Company.”

About Jacobio
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.
For more information, please visit: http://www.jacobiopharma.com